Drug intelligence / Profile preview

MXE 2049

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral, Intranasal, Intravenous, Intramuscular, Rectal, Sublingual, Intraperitoneal

Overview

MXE 2049 is a small molecule myxobacterial metabolite identified for its potential therapeutic applications in Parkinson's disease. It has demonstrated the ability to increase cell growth rate, promote the regeneration of cells in a Parkinson's disease mouse model, and reduce the levels of proteins associated with endoplasmic reticulum stress and apoptotic cell death. These properties suggest its role in neuroprotection and cellular repair, making it a candidate for novel Parkinson's disease therapies.

Beyond the preview

Go deeper on MXE 2049.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MXE 2049.

Explore the full profile